CTRI/2026/07/113659进行中（未招募）3 期
A Prospective, Randomized, Double Blind, Placebo Controlled, Parallel Group, Three Arm Study to Evaluate the Efficacy and Safety of Dose for Blood Pressure Shot DBPS in Prehypertensive Participants - NIL
Eetho Brands Inc0 个研究点目标入组 198 人开始时间: 2026年7月30日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female aged between 40 and 65 years inclusive, at the time of signing informed consent form.
- •Seated clinic systolic blood pressure SBP 120 & 139 mmHg and diastolic blood pressure DBP 80 & 89 mmHg confirming a prehypertensive state as per JNC7 and WHO guidelines. Blood pressure will be determined by repeated measurements using a mercury sphygmomanometer Refer Appendix
- •3.In good general health, as determined by a medical history, physical examination, vital signs, electrocardiogram ECG, and routine clinical laboratory tests hematology, clinical chemistry, urinalysis.
- •4.Body Mass Index 30 kgm
- •5.Female of childbearing potential WOCBP must agree to use a highly effective method of contraception e.g., oral contraceptives, intrauterine device, surgical sterilization from screening until the end of the study. Female who are postmenopausal defined as amenorrhea for at least 12 consecutive month or surgically sterile are eligible.
- •6.Ability and willingness to provide written informed consent to participate in the study after all procedures have been fully explained and questions have been answered.
- •7.Willing and able to comply with all study procedures, visit schedules, and study-related restrictions.
排除标准
- •1.Diagnosed with Stage 1 Hypertension SBP139 mmHg or DBP89 mmHg or Stage 2 Hypertension per JNC 7 and WHO guidelines.
- •2.Evidence of secondary hypertension e.g. renal artery stenosis, primary hyperaldosteronism, sleep apnea.
- •3.History of significant cardiovascular disease, including but not limited to
- •4.Use of any medications prescription, over the counter, herbal supplements, certain vitamins minerals known to affect blood pressure or interfere with study product absorption metabolism within 14 days prior to the dosing visit, or unwillingness to stop them for the study duration.
- •5.Organ Function Impairment
- •History of uncontrolled diabetes mellitus e.g. HbA1c 7 0 or other chronic diseases that may interfere with study participation or pose additional risk to the participant.
- •Current smoker or use of nicotine products. Define as self reported tobacco or nicotine use including cigarettes, bidis, chewing tobacco, e cigarettes vapes, nicotine gum patches within the 30 days prior to screening, or intention to use during study participation.
- •Excessive alcohol consumption 2 alcoholic drinks per day for men and greater than 1 alcoholic drink per day for female.
- •9.History of substance abuse or dependency within the last 2 years.
- •10.Female who are pregnant or lactating.
- •11.History of hypersensitivity or contraindication to the test product Dose for Blood Pressure Shot 59 mL or any of its components or placebo.
- •12.Participation in another clinical research study involving an investigational product within 30 days prior to screening or during the current study.
研究者
相似试验
尚未招募
不适用
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionjRCT2031260211348
招募中
1 期
A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain2025-523737-26-00Centrexion Therapeutics Corp.20
招募中
1 期
A Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 1b Study to Assess the Safety, Immunogenicity and Pharmacodynamics of TRB-001 in Early Idiopathic Parkinson’s Disease PatientsParkinson's disease2024-519123-14-00Tridem Bioscience FlexCo18
尚未招募
不适用
A Study to Evaluate Atumelnant in Adults with Congenital Adrenal HyperplasiaClassic Congenital Adrenal HyperplasiajRCT203126019410
招募中
不适用
A dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of galvokimig in adult study participants with atopic dermatitisAtopic dermatitisjRCT203125061920